Some studies have confirmed higher circulating MCP-1 in patients with nonalcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD), when compared to healthy controls [36,38]. Here, CCL2 is linked to metabolic dysfunction-associated steatotic liver disease.